報價延遲最少15分鐘:2026/08/05 18:00 EDT
盤後時段
|
||||
|
0.3479 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3402
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.46/--
|
|
企業價值
7.95M
|
| 資產負債 |
|
每股賬面淨值
0.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
301.65K
|
|
每股收益
0.03
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the US and China, with China generating the maximum sales. |
